Status:
RECRUITING
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Peking University First Hospital
The First Affiliated Hospital of Zhengzhou University
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
15-70 years
Brief Summary
Presently, multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) have been used for disease load, including measurable residual disease (MRD), monitoring in patients with myelodyspla...
Eligibility Criteria
Inclusion
- Patients with Myelodysplastic syndromes;
- Between 15 and 70 years old;
- Subjects are able to provide written informed consent.
Exclusion
- Subjects who cannot comply with the study;
- Patient has severe cardiac (ejection fraction \<50%), hepatic (total bilirubin \>34μmol/L, ALT, AST \>2x upper limit of normal) or renal (blood creatinine \>130μmol/L) disease；
- Uncontrolled serious infection;
- Other conditions that do not tolerate transplantation or other therapies.
Key Trial Info
Start Date :
December 9 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 18 2027
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT06569095
Start Date
December 9 2024
End Date
December 18 2027
Last Update
December 20 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, China
2
Peking University People's Hospital
Beijing, China
3
Wuhan TongJi Hospital
Wuhan, China
4
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China